GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze

10.1158/1538-7445.sabcs18-ot3-05-01 ◽

2019 ◽

Author(s):

CE Geyer ◽

S Loibl ◽

P Rastogi ◽

S Seiler ◽

JP Costantino ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Abstract OT2-04-08: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze

10.1158/1538-7445.sabcs19-ot2-04-08 ◽

2020 ◽

Author(s):

Charles E Geyer ◽

Sibylle Loibl ◽

Priya Rastogi ◽

Sabine Seiler ◽

Joseph P Costantino ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps603 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS603-TPS603 ◽

Cited By ~ 2

Author(s):

Charles E. Geyer ◽

Sibylle Loibl ◽

Priya Rastogi ◽

Sabine Seiler ◽

Joseph P. Costantino ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

248TiP A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.369 ◽

2020 ◽

Vol 31 ◽

pp. S339

Author(s):

S. Loibl ◽

P. Rastogi ◽

S. Seiler ◽

C. Jackisch ◽

P.C. Lucas ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial

Abstract PD6-07: Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

10.1158/1538-7445.sabcs17-pd6-07 ◽

2018 ◽

Author(s):

L Buisseret ◽

S Pommey ◽

B Allard ◽

S Garaud ◽

MA Bergeron ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Clinical Significance ◽

Triple Negative ◽

Phase Iii ◽

Phase Iii Clinical Trial ◽

Cd73 Expression

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

Annals of Oncology ◽

10.1093/annonc/mdx730 ◽

2018 ◽

Vol 29 (4) ◽

pp. 1056-1062 ◽

Cited By ~ 50

Author(s):

L. Buisseret ◽

S. Pommey ◽

B. Allard ◽

S. Garaud ◽

M. Bergeron ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Clinical Significance ◽

Triple Negative ◽

Phase Iii ◽

Phase Iii Clinical Trial ◽

Multiplex Analysis

Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

Annals of Oncology ◽

10.1093/annonc/mdx138.005 ◽

2017 ◽

Vol 28 ◽

pp. i11 ◽

Cited By ~ 1

Author(s):

L. Buisseret ◽

S. Pommey ◽

B. Allard ◽

S. Garaud ◽

L. Ameye ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Clinical Significance ◽

Triple Negative ◽

Phase Iii ◽

Phase Iii Clinical Trial ◽

Cd73 Expression

A randomized, double-blind, phase III trial of neoadjuvant chemotherapy with Atezolizumab/Placebo in patients with triple-negative breast cancer followed by adjuvant continuation of Atezolizumab/Placebo (GeparDouze)

10.1055/s-0038-1651756 ◽

2018 ◽

Author(s):

S Loibl ◽

C Jackisch ◽

S Seiler ◽

P Rastogi ◽

JU Blohmer ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial

IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1093/annonc/mdy424.008 ◽

2018 ◽

Vol 29 ◽

pp. viii707-viii708 ◽

Cited By ~ 3

Author(s):

P. Schmid ◽

S. Adams ◽

H.S. Rugo ◽

A. Schneeweiss ◽

C.H. Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

Double Blind ◽

Treatment Naïve ◽

Phase Iii Study

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1093/annonc/mdx656 ◽

2017 ◽

Vol 28 ◽

pp. x25

Author(s):

J. Cortes Castan ◽

Z. Guo ◽

V. Karantza ◽

G. Aktan

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Study ◽

Locally Recurrent